In a story about a Portland area resident who says they experienced a minor delayed allergic reaction from a COVID vaccination, an OHSU spokesperson is quoted as saying “while allergic reactions can be uncomfortable, it’s up to each individual to weigh the risk of a possible allergic reaction against the risk of serious illness due to COVID-19 infection, in consultation with their primary care provider or specialist as appropriate.”
In a story about new research highlighting inaccurate results among patients with darker skin tones monitored with a pulse oximeter, Gopal Allada, M.D., says, “It triggers a lot of conversations within people who use the tool.”
In a story about how to convince more people to get a COVID vaccine when they can, David Bangsberg, M.Sc., M.D., M.P.H., notes low vaccination rates recently caused measles outbreaks in Oregon.
OHSU issues a statement, which starts with “OHSU and has been from the beginning, a strong advocate for broad, efficient vaccine distribution to those with the greatest need, including community providers and vulnerable populations.”
American Association for Cancer Research
January 19, 2021
Robert Eil, M.D., is awarded a grant from the AACR-MPM Oncology Charitable Foundation Transformative Cancer Research Program to test the hypothesis that cancer cell death suppresses T-cell function through potassium (K+)-sensitive signal transduction
A cover story investigates the sudden bankruptcy of IVF financing firm IntegraMed and applauds OHSU for honoring the company’s financing packages to ensure patients are able to obtain care.
A feature story about the emergence of new coronavirus variants includes comment from Benjamin Bimber, Ph.D. He says: “The only way to [stop emergence of new variants] is to stop the spread of the virus…Every time the virus replicates, it’s an opportunity to mutate:”
OHSU Doernbecher and Nike announce a virtual installment of the annual Doernbecher Freestyle event to safely help raise funds for the children’s hospital despite the pandemic.
Mark Pennesi, M.D., Ph.D., is leading OHSU’s involvement in a Phase 2a clinical trial evaluating an experimental human retinal progenitor cell therapy as a potential treatment for the blindness-causing disorder retinitis pigmentosa.